LUX-Lung 3 Trial Design

Interview with Prof Tony Shu Kam Mok, MD
Department of Clinical Oncology,
Chinese University of Hong Kong,
Hong Kong

01.05.2012

Q. What can you tell us about the LUX-Lung 3 trial design?

A. How this study is conducted is actually important. This is one of the few randomised controlled study that actually select the patient with EGFR mutation, and then randomise to either irreversible TKI, which is afatinib*, or a standard best in the class chemotherapy of pemetrexed and cisplatinum. Now first of all the EGFR mutation they actually selected the patient who have the mutation in either exon 19 or 21 or categorised as the other mutation, which are the exon 18 and exon 20 mutations. Now, majority of the patients with EGFR exon 19 and 21 who have a significant, a good response to the standard TKI, so particularly in this study we look into this category of patient with these so-called common mutations and how does it compare to standard chemotherapy?